{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:14:15Z","timestamp":1788520455652,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Stat Methods Med Res"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Randomized controlled trials in oncology often allow control group participants to switch to experimental treatments, a practice that, while often ethically necessary, complicates the accurate estimation of long-term treatment effects. When switching rates are high or sample sizes are limited, commonly used methods for treatment switching adjustment (such as the rank-preserving structural failure time model, inverse probability of censoring weights, and two-stage estimation) may produce imprecise estimates. Real-world data can be used to develop an external control arm for the randomized controlled trial, although this approach ignores evidence from trial subjects who did not switch and ignores evidence from the data obtained prior to switching for those subjects who did. This article introduces \u201caugmented two-stage estimation\u201d (ATSE), a method that combines data from non-switching participants in a randomized controlled trial with an external dataset, forming a \u201chybrid non-switching arm\u201d. While aiming for more precise estimation, the augmented two-stage estimation requires strong assumptions. Namely, conditional on all the observed covariates: (1) a participant's decision to switch treatments must be independent of their post-progression survival, and (2) individuals from the randomized controlled trial and the external cohort must be exchangeable. With a simulation study, we evaluate the augmented two-stage estimation method's performance compared to two-stage estimation adjustment and an external control arm approach. Results indicate that performance is dependent on scenario characteristics, but when unconfounded external data are available, augmented two-stage estimation may result in less bias and improved precision compared to two-stage estimation and external control arm approaches. When external data are affected by unmeasured confounding, augmented two-stage estimation becomes prone to bias, but to a lesser extent compared to an external control arm approach.<\/jats:p>","DOI":"10.1177\/09622802251374838","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:03:56Z","timestamp":1759262636000},"page":"2249-2269","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-1594","authenticated-orcid":false,"given":"Harlan","family":"Campbell","sequence":"first","affiliation":[{"name":"Department of Statistics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5304-5585","authenticated-orcid":false,"given":"Nicholas","family":"Latimer","sequence":"additional","affiliation":[{"name":"University of Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P","family":"Jansen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-9485","authenticated-orcid":false,"given":"Shannon","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-10"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr386"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx793"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/S026646231600009X"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/03610929108830654"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00779.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280214557578"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-4"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1602"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1017\/S026646231600026X"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3164_332"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0070"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.02.1182"},{"key":"e_1_3_4_15_2","unstructured":"Hoyle M Rogers G Garside R et al.Commissioned by NHS R&D HTA ProgrammeThe clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. 2008. https:\/\/researchers.mq.edu.au\/en\/publications\/the-clinical-and-cost-effectiveness-of-lenalidomide-for-multiple-."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","unstructured":"Latimer NR Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310374\/.","DOI":"10.1016\/j.jval.2013.08.013"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0175"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.015"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-022-00155-y"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2841"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6923"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280218780856"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa213"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.05.016"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1009212673"},{"key":"e_1_3_4_26_2","first-page":"639","article-title":"Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models","volume":"7","author":"Hobbs BP","year":"2012","unstructured":"Hobbs BP, Sargent DJ, Carlin BP. Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. Bayesian Analysis (Online) 2012; 7: 639.","journal-title":"Bayesian Analysis (Online)"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12242"},{"key":"e_1_3_4_28_2","article-title":"LEAP: the latent exchangeability prior for borrowing information from historical data","volume":"80","author":"Alt EM","year":"2024","unstructured":"Alt EM, Chang X, Jiang X, et al. LEAP: the latent exchangeability prior for borrowing information from historical data. Biometrics 2024; 80: ujae083.","journal-title":"Biometrics"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomtc\/ujae084"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.101000"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280220912524"},{"key":"e_1_3_4_33_2","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2011."},{"key":"e_1_3_4_34_2","unstructured":"Greifer N Greifer MN. Package \u2018WeightIt\u2019. CRANhttps:\/\/cranr-project org\/web\/packages\/WeightIt\/index html 2019."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2120"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00944-1"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"Fu EL Harhay M Schneeweiss S et al. Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial. Available at SSRN 5177135 2025. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=5177135.","DOI":"10.2139\/ssrn.5177135"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.014"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.01.021"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9810"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz137"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz076"}],"container-title":["Statistical Methods in Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09622802251374838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09622802251374838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09622802251374838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:01:43Z","timestamp":1764777703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09622802251374838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/09622802251374838"],"URL":"https:\/\/doi.org\/10.1177\/09622802251374838","relation":{},"ISSN":["0962-2802","1477-0334"],"issn-type":[{"value":"0962-2802","type":"print"},{"value":"1477-0334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}